Literature DB >> 12870562

Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology.

G M Goodwin1.   

Abstract

The British Association for Psychopharmacology guidelines specify the scope and target of treatment for bipolar disorder. They are based explicitly on the available evidence and presented, similar to previous Clinical Practice guidelines, as recommendations to aid clinical decision-making for practitioners. They may also serve as a source of information for patients and carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up after extensive feedback from participants and interested parties. The strength of supporting evidence was rated. The guidelines cover the diagnosis of bipolar disorder, clinical management and strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870562     DOI: 10.1177/0269881103017002003

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  50 in total

1.  Case report: Successful riluzole augmentation therapy in treatment-resistant bipolar depression following the development of rash with lamotrigine.

Authors:  Jaskaran Singh; Carlos A Zarate; Andrew D Krystal
Journal:  Psychopharmacology (Berl)       Date:  2004-01-14       Impact factor: 4.530

2.  [A new evidence and consensus-based German guidelines for diagnosis and treatment of bipolar disorders].

Authors:  M Bauer
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

3.  Cost effectiveness of quetiapine in patients with acute bipolar depression and in maintenance treatment after an acute depressive episode.

Authors:  Mattias Ekman; Peter Lindgren; Carolin Miltenburger; Genevieve Meier; Julie C Locklear; Mary Lou Chatterton
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

4.  Bipolar disorder--services need to catch up with rapidly developing evidence base.

Authors:  John Geddes
Journal:  BMJ       Date:  2006-01-07

Review 5.  Reluctance to disclose difficult diagnoses: a narrative review comparing communication by psychiatrists and oncologists.

Authors:  Alex J Mitchell
Journal:  Support Care Cancer       Date:  2007-07       Impact factor: 3.603

Review 6.  Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder.

Authors:  Toni M Dando; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 7.  Aripiprazole: in acute mania associated with bipolar I disorder.

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 8.  Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review.

Authors:  Hans-Jürgen Möller; Heinz Grunze; Karl Broich
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-08-04       Impact factor: 5.270

9.  Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy.

Authors:  Yogita Ghodke Puranik; Angela K Birnbaum; Susan E Marino; Ghada Ahmed; James C Cloyd; Rory P Remmel; Ilo E Leppik; Jatinder K Lamba
Journal:  Pharmacogenomics       Date:  2013-01       Impact factor: 2.533

10.  Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?

Authors:  H-J Lee; J S Rao; L Chang; S I Rapoport; H-W Kim
Journal:  Mol Psychiatry       Date:  2008-11-04       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.